 | |
| Names | |
|---|---|
| IUPAC name N,N-Diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl)benzamide | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| UNII | |
| |
| |
| Properties | |
| C24H28N2O3 | |
| Molar mass | 392.499 g·mol−1 |
| Related compounds | |
Related compounds | ADL-5747 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
ADL-5859, also known ascompound 20, is an opioid drug that is selective for theδ-opioid receptor, it is being investigated as an alternative to traditional opioids in pain management.
Like all opioid drugs, ADL-5859 activates opioid receptors, but where as traditional opioids (such asoxycodone) activate the three main receptors (mu,delta, andkappa), ADL-5859 appears to be selective and only activates the delta receptor.[1] with a Ki of 20 nM
Like other opioids, it has potential in pain management; however, by being selective for the delta receptor, multiple undesirable side effects of traditional opioids are not present, such as respiratory depression, sedation, and euphoria.
ADL-5859 was also found to be orally active, which makes it easier to administer.[2]
Multiple tests have shown its efficacy as an analgesic.[3][1] It also did not seem to be a convulsant, unlike some other delta agonist opioids.[4]